Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NOVAFED vs ACTIFED
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Novafed contains pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
FDA: Relief of nasal congestion due to common cold, hay fever, or other respiratory allergies,Off-label: Sinus congestion, eustachian tube congestion
Temporary relief of symptoms associated with allergic rhinitis (sneezing, rhinorrhea, pruritus),Temporary relief of nasal congestion due to common cold, hay fever, or other upper respiratory allergies
1-2 capsules orally every 12 hours; each capsule contains pseudoephedrine HCl 120 mg and dextromethorphan HBr 30 mg.
1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.
Terminal elimination half-life: 4-8 hours (mean 5-6 hours); prolonged in renal impairment (up to 20 hours) and with urinary alkalinization; in patients with normal renal function, steady-state is achieved after 2-3 days of every-6-hour dosing.
Triprolidine: 3.2 hours; Pseudoephedrine: 5–8 hours (p H-dependent: alkaline urine prolongs). Terminal half-life for clinical use typically 4–6 hours.
Pseudoephedrine is partially metabolized in the liver by N-demethylation to an inactive metabolite. It is excreted primarily unchanged in urine (70-90%).
Triprolidine: Hepatic metabolism via CYP450 enzymes. Pseudoephedrine: Partially metabolized in liver by N-demethylation; excreted unchanged in urine (70-90%).
Renal elimination of unchanged drug and metabolites; approximately 60-70% of a dose is excreted in urine as unchanged pseudoephedrine within 24 hours; the remainder is metabolized hepatically and excreted renally; minimal biliary/fecal elimination (<5%).
Renal: 80% (20% unchanged, 60% as metabolites). Fecal: 20% (unchanged and metabolites). Active tubular secretion of pseudoephedrine.
Approximately 20-25% bound to plasma proteins (mainly albumin).
Triprolidine: 60% bound to serum albumin; Pseudoephedrine: 20–30% bound to plasma proteins (mainly albumin).
Apparent volume of distribution (Vd): 2.5-3.5 L/kg; indicates extensive tissue distribution (e.g., into respiratory mucosa, CNS); Vd is increased in obesity.
Triprolidine: 2.5–4.0 L/kg; Pseudoephedrine: 2.6–3.5 L/kg. Indicates extensive tissue distribution.
Oral bioavailability: approximately 100% for immediate-release tablets; pseudoephedrine is well absorbed with high systemic availability; extended-release forms have similar extent of absorption but with slower rate.
Oral: Triprolidine 90–100%; Pseudoephedrine 100% (first-pass metabolism negligible).
Cr Cl 30-50 m L/min: administer every 12 hours; Cr Cl 10-29 m L/min: administer every 24 hours; Cr Cl <10 m L/min: not recommended.
Cr Cl 30-50 m L/min: extend dosing interval to every 8 hours. Cr Cl 15-29 m L/min: every 12 hours. Cr Cl <15 m L/min: not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: administer every 12 hours; Child-Pugh Class C: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: consider extending interval to every 8 hours. Child-Pugh C: avoid use.
Children 6-12 years: 1/2 capsule orally every 12 hours; children <6 years: not recommended.
Children 6-12 years: 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 6 hours; max 2 tablets/24 hours. Children <6 years: not recommended.
Initiate at lower end of dosing range (1 capsule every 12 hours) due to increased sensitivity and potential for adverse effects; monitor renal function.
Start with 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 8 hours; monitor for CNS excitation and anticholinergic effects.
No FDA black box warning.
None.
Use with caution in patients with hypertension, cardiovascular disease, diabetes, glaucoma, hyperthyroidism, prostatic hypertrophy, and in elderly. May cause insomnia, nervousness, and elevated blood pressure.
Cardiovascular effects: hypertension, palpitations, tachycardia, arrhythmias,CNS stimulation: nervousness, dizziness, insomnia, especially in elderly,May cause urinary retention in patients with prostatic hypertrophy,Use caution in patients with diabetes, hyperthyroidism, ischemic heart disease, increased intraocular pressure,Anticholinergic effects: dry mouth, blurred vision, constipation
Severe hypertension, severe coronary artery disease, narrow-angle glaucoma, urinary retention, concurrent use of MAO inhibitors or within 14 days of stopping, and hypersensitivity to pseudoephedrine.
Hypersensitivity to triprolidine, pseudoephedrine, or any component,Severe hypertension or coronary artery disease,Monoamine oxidase inhibitor (MAOI) therapy (concurrent or within 14 days),Narrow-angle glaucoma,Urinary retention,During or within 14 days of MAOI use
Avoid concurrent use with caffeinated beverages or foods as they may increase nervousness and insomnia. Alcohol should be avoided as it can exacerbate side effects. No significant food-drug interactions with other items.
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) as pseudoephedrine may potentiate vasopressor effects. Grapefruit juice may decrease pseudoephedrine absorption; separate administration by at least 4 hours.
First trimester: Inadequate human data; animal studies show no teratogenicity at therapeutic doses. Second/third trimester: Potential for uterine artery vasoconstriction reducing placental perfusion; risk of fetal tachycardia. Avoid in pregnancy unless benefit outweighs risk.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Avoid unless benefit outweighs risk. Second/third trimesters: Risk of premature labor, neonatal respiratory depression, and withdrawal symptoms with prolonged use. Use lowest effective dose for shortest duration.
Pseudoephedrine (active ingredient in NOVAFED) is excreted into breast milk; M/P ratio not determined. May reduce milk production. Use with caution; monitor infant for irritability and sleep disturbances.
Pseudoephedrine is excreted into breast milk; M/P ratio approximately 3.5. Triprolidine is present in milk. Potential for irritability, sleep disturbance in infants; may reduce milk supply. Use with caution; alternative preferred. Discontinue breastfeeding or drug based on necessity.
No specific dose adjustment recommended; use lowest effective dose and shortest duration. Increased plasma volume in pregnancy may reduce drug levels but no data to support dose increase due to potential maternal-fetal risks.
No specific dose adjustment recommended for pregnancy; however, increased plasma volume may reduce drug concentrations. Use lowest effective dose due to limited safety data. Avoid in hypertension or preeclampsia.
NOVAFED contains pseudoephedrine and is contraindicated in patients with severe hypertension or coronary artery disease. Monitor blood pressure closely. Onset of action is 30-60 minutes; do not exceed 240 mg/day. Avoid use with MAOIs or within 14 days of stopping them.
Actifed (pseudoephedrine + triprolidine) is contraindicated in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Pseudoephedrine can cause CNS stimulation and insomnia, so avoid evening dosing. Triprolidine is a first-generation antihistamine with significant anticholinergic effects; use caution in elderly or those with BPH, urinary retention, or asthma.
Do not crush or chew extended-release tablets.,Stop use if you experience rapid heartbeat, dizziness, or difficulty urinating.,Avoid taking close to bedtime to prevent insomnia.,Do not take with other cold or allergy medications containing decongestants.,Consult a doctor if symptoms persist after 7 days or are accompanied by fever.
Do not take with other cold or allergy medications containing decongestants or antihistamines.,Avoid alcohol and sedatives as they may increase drowsiness.,Do not crush or chew extended-release tablets; swallow whole.,Monitor for increased blood pressure or heart rate; discontinue if palpitations occur.,May cause dizziness; avoid driving or operating heavy machinery until you know how it affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NOVAFED vs ACTIFED, answered by our medical review team.
NOVAFED is a Decongestant that works by Novafed contains pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.. ACTIFED is a Decongestant/Antihistamine Combination that works by ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NOVAFED and ACTIFED depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NOVAFED is: 1-2 capsules orally every 12 hours; each capsule contains pseudoephedrine HCl 120 mg and dextromethorphan HBr 30 mg.. The standard adult dose of ACTIFED is: 1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NOVAFED and ACTIFED in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NOVAFED is classified as Category C. First trimester: Inadequate human data; animal studies show no teratogenicity at therapeutic doses. Second/third trimester: Potential for uterine artery vasoconstriction reducing p. ACTIFED is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Avoid unless benefit outweighs risk. Second/third trimesters: Risk . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.